Navigation Links
MiMedx Announces Record Second Quarter Results
Date:7/31/2013

MARIETTA, Ga., July 31, 2013 /PRNewswire/ -- MiMedx Group, Inc.  (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the quarter ended June 30, 2013.

Highlights of second quarter 2013 results include:

  • Revenue met or exceeded  forecast for 7th consecutive quarter
  • Revenue increased more than 175% over second quarter of 2012
  • Six-month revenue increased more than 190% over first half of 2012
  • Sixth consecutive quarter of positive Adjusted EBITDA
  • Gross Margins improved by 7% over second quarter of 2012
  • Six month gross margins improved 8% over prior year
  • Company reiterates third quarter and full year 2013 guidance
  • Second Quarter 2013 Results
    The Company recorded record revenue of $13.51 million for the quarter ended June 30, 2013, an increase of more than 175% over second quarter of 2012 revenue of $4.88 million. The Company's second quarter gross margins were 84% as compared to gross margins of 77% in the second quarter of last year.  Earnings before interest, taxes, depreciation, amortization and share based compensation, non-cash impairment and earn out liability charges (Adjusted EBITDA) for the second quarter of 2013 were $1.17 million, a $242,000  or 26% improvement as compared to the Adjusted EBITDA  of $923,000 for the second quarter of 2012. The Net Loss for the second quarter of 2013 was $757,000 as compared to the Net Loss of $744,000 in the second quarter of the prior year.

    For the six months ended June 30, 2013, the Company recorded record revenue of $25.07 million, an increase of more than 190% over revenue of $8.59 million recorded for the first six months
    '/>"/>

    SOURCE MiMedx Group, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
    2. MiMedx To Exceed High End Of Second Quarter Guidance
    3. MiMedx to Ring NASDAQ Stock Market Opening Bell
    4. MiMedx to Present at Jefferies 2013 Global Healthcare Conference
    5. MiMedx Secures a $3.0 Million Revolving Line of Credit with Bank of America
    6. MiMedx Announces Record First Quarter 2013 Results
    7. MiMedx Group, Inc. Announces Listing on the NASDAQ Capital Market
    8. MiMedx Group, Inc. Announces Release Date for 2013 First Quarter Results
    9. MiMedx Responds To Inquiries Regarding Trading Activity; Reiterates First Quarter And Full Year Goals
    10. MiMedx to Present at the Canaccord Genuity Musculoskeletal Conference
    11. MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/1/2015)... and PARIS , July 1, ... Genective, key developer of biotech crops, today announce ... new generations of insect control traits. ... counter the realities of advancing insect resistance. We ... unique insect control technology with Genective,s capability in ...
    (Date:7/1/2015)... 2015  Axovant Sciences Ltd. (NYSE:  AXON), a ... of dementia, today announced that the company will ... 5:45 p.m. EDT following its presentation of RVT-101 ... 2015 (AAIC). The event will ... Lawrence Friedhoff , Chief Development Officer, will ...
    (Date:7/1/2015)... ... July 01, 2015 , ... NEMA 4 (IP66) Medical Joysticks ... Medical Joysticks have an impermeable molecular barrier protection against bio-hazardous agents. Original ... will increase healthcare worker safety and reduce financial costs. , CTI Electronics announces ...
    (Date:6/30/2015)... ... 30, 2015 , ... Park Systems , world-leader in ... into new classes of Nanoscale Graphene-based materials poised to revolutionize industries such as ... of the 21st Century' by the researchers who were awarded the 2010 Nobel ...
    Breaking Biology Technology:AgBiome and Genective collaborate to create novel insect-resistant crops 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 2How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 3How Graphene–based Nanomaterials and Films Revolutionize Science Explained in July 9 Webinar Hosted by Park Systems 4
    ... SAN DIEGO, Jan. 6, 2011 Ardea Biosciences, Inc. ... top-line results from its Phase 2b study of RDEA594 ... the treatment of gout, allopurinol.  Allopurinol currently accounts for ... gout prescription medications; however, in controlled trials, only 30-40% ...
    ... Jan. 6, 2011 Vista Partners announced today ... (Nasdaq: OPXA ) and raised its twelve ... Analyst at Vista Partners stated, "Opexa announced yesterday that their ... treatment of Multiple sclerosis , is now positioned from ...
    ... 2011 GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical ... focusing on the early diagnosis and preventive treatment of ... two U.S. events: the 28th J.P. Morgan Healthcare Conference ... Showcase (from January 10th to 12th, 2011). ...
    Cached Biology Technology:Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 2Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 3Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 4Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 5Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 6Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients 7Vista Partners Updates Coverage on Opexa Therapeutics, Inc.; Raises Target Price From $4.40 to $6.50 2GENFIT: Strong U.S. Exposure for Its Biomarker Activity 2GENFIT: Strong U.S. Exposure for Its Biomarker Activity 3
    (Date:7/2/2015)... Fingerprint Cards has received an order ... from the distributor World Peace Industrial Group (WPI), part of ... Asia . Deliveries are planned to take place ... by smartphone manufacturers in Asia . The ... revenue guidance of approximately 2,200 MSEK for 2015. ...
    (Date:6/25/2015)... 2015 According to a ... & Area), Technology, Material (Optical Prism, Piezoelectric, Capacitive ... & Others) & Geography - Global Forecast to ... market is expected to reach $14,500.07 Million by ... Browse 76 market Tables and 109 Figures ...
    (Date:6/24/2015)... 24, 2015  Synaptics Inc. (NASDAQ: SYNA ... today announced that Sharp has selected its industry-leading ... for its latest flagship smartphone device, the AQUOS ... million shipments of its fingerprint ID sensor technology, ... scalability and leadership in the biometrics market through ...
    Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2
    ... British Columbia researchers have identified a small virus that ... size, rescuing the infected zooplankton from certain death. The ... jumping genes found in other organisms. The study, ... Matthias Fischer, is published online today in Science Express. ...
    ... at managing environmental impacts of agriculture have spurred ... and natural fertilizers for commercial applications. Many organic ... other processing industries. In Mississippi, where the poultry ... each year, and annual chicken litter production is ...
    ... New University of Georgia research has identified a protein ... of the most common drugs used to treat pancreatic cancer. ... journal Cancer Research, found that a cell-surface protein ... reduced in function in two thirds of pancreatic tumors. By ...
    Cached Biology News:'David and Goliath' viruses shed light on the origin of jumping genes: UBC study 2Chicken litter provides organic alternative to synthetic fertilizers 2Researchers find possible new treatment strategies for pancreatic cancer 2
    ... Fluoroskan Ascent is a ... flexibility for all kinds of ... research and for clinical applications. ... biology are all important application ...
    ... SpeedVac Concentrator, the SPD series takes the ... modern twist., The SPD121P SpeedVac comes equipped ... optimizing runs; preventing samples from freezing; and ... the end-users preset level., Standard features on ...
    ... desktop unit ideal for use in laboratories with ... speed set at 12 rpm , Temperature ... Bottle capacity of four 35 x 150mm bottles, ... bottles , Consistent, repeatable results achieved with ...
    ... Savant SpeedVac Concentrators set the standard for centrifugal ... uses a combination of centrifugal force, heat and ... run., SC110A comes equipped with:, , TEFLON-coated ... , Three ...
    Biology Products: